2009

Peripheral Dendritic Cells Are Essential for Both the Innate and Adaptive Antiviral Immune Responses in the Central Nervous System

Christina D. Steel  
*Old Dominion University, csteel@odu.edu*

Suzanna M. Hahto

Richard P. Ciavarra

Follow this and additional works at: [https://digitalcommons.odu.edu/biology_fac_pubs](https://digitalcommons.odu.edu/biology_fac_pubs)

Part of the [Cell Biology Commons](https://digitalcommons.odu.edu/cellbiology), and the [Virology Commons](https://digitalcommons.odu.edu/virology)

Repository Citation

[https://digitalcommons.odu.edu/biology_fac_pubs/329](https://digitalcommons.odu.edu/biology_fac_pubs/329)

Original Publication Citation

Peripheral dendritic cells are essential for both the innate and adaptive antiviral immune responses in the central nervous system

Christina D. Steel, Suzanne M. Hahto, Richard P. Ciavarra *

Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, 700 W Olney Road, Norfolk, VA 23501, USA

A R T I C L E   I N F O

Article history:
Received 23 October 2008
Returned to author for revision
18 November 2008
Accepted 22 January 2009
Available online 4 March 2009

Keywords:
Microglia
Dendritic cells
Viral encephalitis
Vesicular stomatitis virus

A B S T R A C T

Intranasal application of vesicular stomatitis virus (VSV) causes acute infection of the central nervous system (CNS). However, VSV encephalitis is not invariably fatal, suggesting that the CNS may contain a professional antigen-presenting cell (APC) capable of inducing or propagating a protective antiviral immune response. To examine this possibility, we first characterized the cellular elements that infiltrate the brain as well as the activation status of resident microglia in the brains of normal and transgenic mice acutely ablated of peripheral dendritic cells (DCs) in vivo. VSV encephalitis was characterized by a pronounced infiltrate of myeloid cells (CD45highCD11b+) and CD8+ T cells containing a subset that was specific for the immunodominant VSV nuclear protein epitope. This T cell response correlated temporally with a rapid and sustained upregulation of MHC class I expression on microglia, whereas class II expression was markedly delayed. Ablation of peripheral DCs profoundly inhibited the inflammatory response as well as infiltration of virus-specific CD8+ T cells. Unexpectedly, the VSV-induced interferon-gamma (IFN-γ) response in the CNS remained intact in DC-deficient mice. Thus, both the inflammatory and certain components of the adaptive primary antiviral immune response in the CNS are dependent on peripheral DCs in vivo.

© 2009 Elsevier Inc. All rights reserved.

Introduction

The central nervous system (CNS) has long been held as an immunologically privileged site (Galea et al., 2007a). Understanding neurological infections is critical to the treatment of several human diseases including HIV, several herpes viruses, measles, rabies, and possibly multiple sclerosis (Nair et al., 2007; Nelson et al., 2002; Ponomarev et al., 2005a). Most current research in mouse models focuses on experimental autoimmune encephalomyelitis (EAE) and persistent infections such as Theiler's murine encephalomyelitis virus (TMEV), primarily with regard to development of treatments for multiple sclerosis. Although these studies provide insights into the general inflammatory and adaptive immune responses in the CNS, they do not accurately reflect the events during acute viral infection.

Several studies suggest that during CNS inflammation, activated DCs migrate to the cervical lymph nodes (Bailey et al., 2007; Dimier-Poison et al., 2006; Hatterer et al., 2006; Plakhov et al., 1995; Schwob et al., 2001; Velge-Roussel et al., 2000), where they activate naive lymphocytes, which then emigrate to the site of inflammation. The origin of these cells, whether peripherally-derived or brain-resident, is still contentious. Most research fails to convincingly demonstrate the presence of DC in naive brain parenchyma (Lauterbach et al., 2006; Matyszak and Perry, 1996; Perry, 1998; Serafini et al., 2000), although they are readily detected in perivascular spaces, cerebrospinal fluid, and areas unprotected by the blood–brain barrier (BBB) (Bailey et al., 2007; Fischer and Reichmann, 2001; Karman et al., 2006; Lauterbach et al., 2006; Matyszak and Perry, 1996; McMenamin, 1999; Miller et al., 2007; Newman et al., 2005; Perry, 1998; Serafini et al., 2000; Serot et al., 1997, 1998, 2000). Only a handful of recent studies, such as those by Fabry et al. and Bulloch et al. (Bulloch et al., 2008; Karman et al., 2006), have demonstrated DCs in the naive CNS parenchyma. These studies further indicate that either resident or infiltrating DCs provide APC function essential for propagation of innate and adaptive immunity in the CNS. It should be noted that identification of DCs in the CNS relies on a phenotypic rather than a functional definition for DCs; many of these studies also note that another population of CNS-resident cells may fulfil the role of APC.

Microglia are widely regarded as the most critical resident CNS cells with immunological capacity and represent approximately 10–20% of the brain parenchyma (Havenith et al., 1998; Lawson et al., 1990; Rock et al., 2004; Santambrogio et al., 2001; Town et al., 2005). Several studies imply that microglia are capable of acquiring APC capacity and may be able to initiate and/or propagate the adaptive immune response in the CNS (Fischer and Reichmann, 2001; Juedes and Ruddle, 2001; Mack et al., 2003; Persidsky et al., 1999; Ponomarev et al., 2005a, 2005b; Shortman and Liu, 2002). Identification of the true APC in CNS infections is therefore a controversial area given the conflicting data for DCs and/or microglia as APCs.

In a previous study, we demonstrated that approximately one-third of mice acutely depleted of DC in vivo and infected peripherally with vesicular stomatitis virus (VSV) developed persistent brain...
infections (Ciavarra et al., 2006). These data imply a crucial role for peripheral DCs in mediating CNS immunity. To more directly evaluate this possibility, we induced viral encephalitis in all mice by a single intranasal application of VSV (Barna et al., 1996; Bi et al., 1995a; Huneycutt et al., 1994; Plakhov et al., 1995). The innate and adaptive antiviral immune responses in the CNS were then characterized in normal mice and transgenic mice rendered deficient of peripheral DCs.

**Results**

**VSV encephalitis is characterized by a prominent mixed cellular infiltrate**

We first phenotyped the cells recruited into the brain of mice following intranasal application of VSV. CB6F1 mice were infected with VSV and monitored for signs of illness. Mice became ill approximately 8 days post-infection, and brains were harvested for flow cytometric analysis at this time. Microglia were gated as CD45<sup>lo/hi</sup>CD11b<sup>+</sup> cells (Fig. 1, box in panels a–b) which distinguished them from resident or infiltrating CD45<sup>hi</sup>CD11b<sup>+</sup> macrophages (mΦ) and CD45<sup>hi</sup>CD11b<sup>+</sup> lymphocytes. Microglia accounted for about 20% of cells recovered from normal, uninfected (mock-infected) mice and comprised approximately 90% of CD11b<sup>+</sup> cells. In contrast, brains from mice infected with VSV contained a prominent population of CD45<sup>hi</sup>CD11b<sup>+</sup> mΦ and a smaller population of lymphocytes (CD45<sup>hi</sup>CD11b<sup>+</sup>). Microglia isolated from virus-infected, but not mock-infected brains, expressed MHC class II molecules suggesting an activated state (panels c–d). Mock-infected mice contained only trace numbers of conventional (CD11c<sup>+</sup>PDCA-1<sup>−</sup>) and pDCs (CD11c<sup>+</sup>PDCA-1<sup>+</sup>), CD4<sup>+</sup> and CD8<sup>+</sup> T cells, whereas VSV induced infiltration of conventional CD11c<sup>+</sup> DCs (panels e–f), CD4<sup>+</sup> and CD8<sup>+</sup> T cells (panels g–h) but few NK cells, B cells (panels k–l) and pDCs (panels e–f). A population of B cells (CD45<sup>R</sup>) were noted in naive and infected mice (panels e–f), but these cells did not expand with VSV infection. Staining with tetramers revealed a trace tetramer<sup>+</sup> population in the mock infected brain that expanded following infection with VSV (panels i, j). Although this is not the optimal time for a CD8<sup>+</sup> T cell response (see Fig. 3), there was still an impressive difference in the number of CD8<sup>+</sup>VSV-N T cells present in the mock versus virus infected animals (140 versus 11,000 cells/brain, respectively, data not shown).

**Kinetics of the inflammatory response in the CNS**

The above study demonstrates that VSV recruits a variety of blood cells into the virus-infected brain. However, this study did not provide any insights into either the status of resident microglia or the kinetics of this inflammatory response. To address these questions, mice were inoculated with VSV for various periods of time and the number of microglia and the identity of infiltrating blood cells in the CNS determined by flow cytometry. It is apparent from Fig. 2A (panels a–c) that VSV induced an initial decrease in the number of microglia before a transient microgliosis became evident. Although this is not the optimal time for a CD8<sup>+</sup> T cell response (see Fig. 3), there was still an impressive difference in the number of CD8<sup>+</sup>VSV-N T cells present in the mock versus virus infected animals (140 versus 11,000 cells/brain, respectively, data not shown).

**Fig. 1.** Intranasal application of VSV induces a vigorous mixed cellular infiltrate in the brain. Mice were given either PBS (Mock) or intranasal VSV at 2 x 10<sup>5</sup> PFU (VSV). Eight days post-infection, leukocytes were isolated from the brain and the infiltrate characterized by flow cytometry. Microglia and infiltrating leukocytes were first identified by forward and side scatter profiles. Within this gate microglia were defined as CD11b<sup>+</sup> and CD45<sup>lo/hi</sup> (box in panels a–b) and expression of MHC class II was evaluated on microglia-gated cells (panels c–d). To characterize other infiltrating cell types, we assessed gated leukocytes (forward and side scatter gate) for DCs (panels e–f) and T cell subsets (panels g–h). To identify VSV-N T cells, co-expression of CD11a and tetramers were assessed on gated CD8<sup>+</sup> cells (panels i–j). NK cells and B cells were identified in the leukocyte gate as CD45<sup>hi</sup>CD49b<sup>+</sup> and CD45<sup>lo/hi</sup>CD45R<sup>+</sup>, respectively (panels k–l). This data is derived from the pooled brains of 4 mice per group.
seen in Figs. 1 and 5, this is reflective of a smaller number of events acquired by flow cytometry. This infiltrate population is quantified later (Fig. 5) and is quite small in terms of both percentage and absolute number despite an apparently large population visible in the flow cytometry density plots. Similar kinetics were observed for CD45<sup>high</sup> blood cells (Fig. 2B, panel a). We also detected a gradual and sustained increase in the number of conventional CD11c<sup>+</sup> DCs, although their numbers were small relative to other myeloid and lymphoid elements in the brain (Fig. 2B, panel b). VSV did not induce a significant infiltrate of pDCs, NK and NKT cells at any of the time points tested (Fig. 2B, panel b and data not shown). It should be noted, however, that we have not formally excluded the possibility that the expansion of CD45<sup>high</sup> cells may have included proliferation of resident haematopoietic cells such as perivascular macrophages.

We next defined the kinetics of T cell subset infiltration into the CNS following infection with VSV. In addition, we assessed the specificity of infiltrating CD8<sup>+</sup> cells using class I tetramers specific for the immunodominant epitope (VSV-N<sub>52–59</sub>). Fig. 3 indicates that the brain contained a small basal population of T cells that did not expand for several days after virus infection (panel A). CD8<sup>+</sup> T cells began to infiltrate the brain on day 6, peaked on day 8 and gradually returned to basal levels on day 21–post-infection. Similar kinetics were observed for CD4<sup>+</sup> cells. Virus-specific CD8<sup>+</sup> T cells (VSV-N) were detectable in the draining CLN around day 5, reached maximal clonal expansion two days later and then their numbers rapidly diminished to achieve basal levels (panel B). The accumulation of VSV-N T cells in the brain followed similar kinetics; however, the response in terms of absolute numbers was much smaller relative to the draining CLN (panel B, note different scales). Thus, VSV induces expansion of both CD<sup>+</sup> and CD4<sup>+</sup> T cell populations including CD8<sup>+</sup> T cells specific for the nuclear protein of this virus. These kinetics, defined by flow cytometric analysis, are consistent with immunohistochemical studies reported by Reiss and her colleagues (Bi et al., 1995b; Forger et al., 1991). Based on these kinetics, we performed subsequent studies on day 6 post-infection because leukocyte infiltration including tetramer<sup>+</sup> cells were readily detectable in the CNS and morbidity/mortality were reduced relative to the peak of infection at days 7–8.

**Phenotypic characterization of microglia isolated from encephalitic brains**

The presence of an activated and expanded population of VSV-N T cells in the brains of VSV-infected mice suggests that primary antiviral immune responses may be either initiated and/or propagated in the CNS. If this is true, it implies that the brain possesses a professional APC capable of driving clonal expansion and differentiation of naive CD8<sup>+</sup> T cells. To examine the extent to which microglia may function as APCs, we evaluated microglial expression of several molecules essential for activation of naive T cells during the early stages of the virus infection. Naive microglia of mice express low to intermediate levels of CD45 (Ford et al., 1995; Ponomarev et al., 2005a, 2005b) and CD11b (Ponomarev et al., 2005b), are CD11c<sup>−</sup>, and have a characteristic ramified morphology when resting (Ponomarev et al., 2005b; Santambrogio et al., 2001; Town et al., 2005), although they are slightly smaller than peripheral CD45<sup>high</sup> leukocytes (Ford et al., 1995). As previously reported, the vast majority of microglia from naive mice express undetectable to low levels of MHC class I antigens. However, virtually all microglia (96%) became class I<sup>+</sup> by day 3 with significant (∼50%) class I expression being detected as early as 48 h following infection (Fig. 4, panel A). Although the percentage of class I<sup>+</sup> microglia dramatically increased, reduced yields of microglia during these early time points prevented a corresponding increase in the absolute number of microglia in the VSV-infected brain (Fig. 4B, panel a). Class I expression was sustained for two weeks but eventually waned to achieve mock-infected levels, consistent with CD8<sup>+</sup> infiltration (Fig. 3A). Microglia slowly upregulated class II antigens (Fig. 2B, panel b) and as a result significant co-expression of these
molecules was not seen until day 10 (data not shown). Microglia also upregulated CD11c late during infection, corresponding with onset of morbidity and increased inflammation in the brain (Figs. 4A and B, panel c). Interestingly, high constitutive levels of PD-1 were detected on microglia and virus infection induced further expression of this molecule so that essentially all microglia were PD-1+ two days post-infection (Figs. 4A and B, panel d). The physiological significance of the negative regulator PD-1 during acute viral encephalitis is currently under investigation.

**Impact of peripheral dendritic cell ablation on the inflammatory and primary antiviral immune responses in the CNS**

Our previous results demonstrated that microglia became activated in response to viral infection of the CNS and expressed surface molecules appropriate for antigen presentation. However, DCs also infiltrated the encephalic CNS, complicating the contribution of each of these cell types to viral clearance and host survival. To more precisely define the role of microglia in viral clearance and survivability, DTRtg mice were treated with either PBS (mock) or DT to systemically deplete DCs and infected with VSV via the intranasal route. Mice were monitored for survival, euthanized when moribund, and virus titres determined on the brain and peripheral organs. It is apparent from Fig. 5 (panel A) that the majority (63%) of mice depleted of peripheral DCs did not survive this dose of virus, whereas only 15% of control mice became moribund and had to be euthanized. Decreased survival was associated with delayed viral clearance in the brain in mice depleted of DCs (panel B). As previously reported, VSV was rapidly cleared from peripheral organs even in moribund mice depleted of DCs (Ciavarra et al., 2006). Thus, ablation of peripheral DCs specifically inhibits viral clearance from the CNS and as a result likely contributes to the observed increase in morbidity/mortality.

The inability of mice to efficiently clear VSV from the CNS suggests that the antiviral immune response was impaired in mice depleted of DCs. To assess this possibility, DTRtg mice were treated with either PBS or DT and then infected i.n. with VSV. Six days post-infection, the number of myeloid (CD11b+CD45high) and lymphoid (CD11b−CD45high) cells in the brain was examined by flow cytometry. As expected, microglia were readily detectable as a CD45low/int CD11b+ population (Region 1, R1) in mock-infected mice (Fig. 5B, panel a). No significant changes in the number of microglia were observed in mice treated with DT alone, a result consistent with low endogenous CD11c expression on resting microglia (panel b). However, VSV infection was associated with a microgliosis that was not inhibited by prior DC depletion (compare R1, panels c and d). As expected, infection of the brain induced a potent inflammatory response revealed by the accumulation of a prominent population of CD45high CD11b− cells (R2) in the brains of VSV infected mice. Surprisingly, prior DT treatment profoundly inhibited this infiltrate (panel d). This was evident whether data were expressed as a percentage or absolute number of infiltrating myeloid cells (panel c). Clonal expansion and/ or infiltration of VSV-N T cells into the encephalitic brain were also profoundly suppressed by prior DC ablation (panel d). This response was also suppressed in the CLN of VSV infected mice because 9,940 and 1,902 CD8+ tetramer+ cells were detected in VSV and DT+VSV treated mice, respectively. Thus, DT treatment of transgenic mice ablates DCs but preserves resident microglia. In the absence of peripheral DCs, the inflammatory response as well as the accumulation of clonally expanded CD8+ VSV-specific T cells is markedly suppressed in the CNS.

As demonstrated in Fig. 5 (panel D) a well-defined CD8+ tetramer+ population was present in the encephalic brain despite the small infiltrate of CD45highCD11b− cells (panel C). This apparent contradiction reflects VSV-induced upregulation of CD11b on activated T cells at this time point (data not presented). Thus, most of the infiltrating CD8+ T cells are found in the CD45highCD11b+ gate. This finding is consistent with reports from other inflammation models (Andersson et al., 1994; Bullard et al., 2005; Christensen et al., 2001; Soili-Hanninen et al., 1997).

**Virus-induced cytokine response in the CNS is not dependent on peripheral dendritic cells**

To determine the functional consequences of DC depletion in vivo, we evaluated the VSV-induced IFN-γ response in the CNS and CLNs in mice systemically depleted of DCs. IFN-γ is an important cytokine for host resistance to this virus because of its antiviral activity in the CNS. It should be noted that cells were cultured overnight in ELISPOT plates in the absence of exogenous virus or viral peptide to more accurately estimate the number of actual cytokine-producing cells in vivo. In control mice infected with VSV, few IL-2 or IL-4-secreting cells were detected in the brain and draining CLNs (data not shown). IFN-γ-producing cells were also detected at very low frequencies in the brains of mock-infected mice. However, IFN-γ-producing cells were readily detected in the brains of mice infected with VSV (Fig. 6). In striking contrast to the proliferative response of class I-restricted VSV-N T cells, mice depleted of DCs mounted a normal VSV-induced IFN-γ cytokine response in the CNS. This was consistently observed whether
the data was expressed as frequency (upper panel) or total number of IFN-γ-producing cells per brain (lower panel). Indeed, in some experiments DC ablation actually enhanced this response (data not shown). Although an IFN-γ response could be detected in the CLNs, this response was modest at this time point relative to the CNS (data not presented). Thus, the VSV-induced IFN-γ cytokine response in the CNS is not inhibited by systemic depletion of conventional and pDCs and implicates that T cells are not essential for IFN-γ production; therefore, microglia or other resident CNS cells may be the source of this cytokine.

Discussion

The present understanding of the CNS as an immune privileged site is rapidly changing in response to closer scrutiny. It is no longer held that the BBB is impenetrable because several studies have demonstrated that some areas of the brain are unprotected by a BBB. These areas include the meninges, choroid plexus, circumventricular organs and ventricles (Farina et al., 2007; Galea et al., 2007a). Furthermore, the perivascular spaces in the CNS were initially termed lymphatic clefts by Goldman (Bechmann et al., 2007). Current studies have clearly demonstrated localization of mH to these regions, which may produce a localized region architecturally similar to lymphoid tissue (also known as tertiary lymphoid regions, Galea et al., 2007a).

The relevant cellular elements (DC, T cells, mH) that reside there may be sufficient to drive T cell activation and clonal expansion. This is in keeping with low numbers of activated T cells in the draining cervical lymph nodes despite their presence in the brain, and provides indirect evidence for more direct, site-specific activation of antigen-specific T cells.

The susceptibility to and kinetics of VSV infection in the CNS vary with mouse strain and gender (Barna et al., 1996). The work of Huneycutt et al. demonstrated that VSV antigen is detectable in the olfactory bulb as early as 12 h post-infection and spreads caudally through the forebrain by 7 days post-infection, with only a few areas of the midbrain demonstrating antigen reactivity (Huneycutt et al., 1994). Previous studies by Reiss and colleagues demonstrated a high rate of morbidity/mortality in this model that correlated with high titers of VSV at 7 days post-infection and loss of the BBB function late in the infection. Surviving mice efficiently cleared VSV from the CNS, suggesting that the host can mount an efficient antiviral immune response in the CNS (Barna et al., 1996; Huneycutt et al., 1994; Plakhov et al., 1995). This view is further supported by immunohistochemical studies that demonstrated a VSV-induced CNS infiltrate composed primarily of mH and lymphocytes (Bi et al., 1995a). The kinetics we demonstrated in the CB6F1/DTRtg mouse are similar to those previously reported (Bi et al., 1995b). Starting as early as 3 days post-infection, we observed a mixed infiltrate of leukocytes in the CNS. Consistent with the findings of Bi et al. (1995b), the infiltrate contained primarily mH, DCs, and T cells, but did not include B cells, NK or NKT cells. Macrophage and lymphocyte infiltration of the CNS increased sharply between days 6–8, corresponding with the peak of viral infection and onset of hind-limb paralysis, morbidity, and mortality. By 8 days post-infection, a significant number of both CD4+ and CD8+ T cells (both antigen-specific and nonspecific) had entered the brain. Our data demonstrate that CD8 infiltration coincides with CD4 entry into the brains of infected mice, consistent with previous studies (Ireland and Reiss, 2006).

Microglia become phenotypically similar to DC when activated (Ponomarev et al., 2005a, 2005b; Shortman and Liu, 2002) and can upregulate several cell surface antigens, including MHC I and II, CD80, and CD40 (Ponomarev et al., 2005a, 2005b), and assume a more spheroid shape. Activated microglia can present antigen to CD4+ T cells and secrete various chemokines (Persidsky et al., 1999) that help recruit activated lymphocytes. Additionally, exposure to GM-CSF has been reported to direct the phenotypic and morphologic maturation of naive microglia into DC-like cells (Fischer and Reichmann, 2001). Juedes and Ruddle (2001) showed that CNS derived microglia can stimulate IFN-γ production in T-MOG (myelin oligodendrocyte glycoprotein)-specific lymphocytes. Following these studies, Mack et al. demonstrated that microglia from the inflamed CNS in the presence of antigen can serve as antigen-presenting cells (APC) for myelin proteolipid protein (PLP139–151)-specific T cells, resulting in the production of IFN-γ and cellular proliferation (Mack et al., 2003). Our results demonstrated that microglia upregulated MHC I and II in response to infection, with MHC I appearing as early as 2 days post-infection and MHC II increasing much later during the course of infection (days 6–10). The prompt expression of class I antigens on microglia is consistent with their putative role as APCs in the CNS. Together, these data suggest that microglia express peptide/MHC class I molecules essential for antigen recognition by naive CD8+ T cells. However, we have not detected expression of CD80 and CD86 on microglia isolated from VSV-infected brains although these are preliminary studies that have not examined multiple time points or specific brain regions to detect regional expression of costimulatory molecules on these cells. Nonetheless, even if microglia do not express costimulatory molecules, they can still function as APCs for T cells activated in the CLN or VSV memory cells to further propagate the immune response in the CNS. Thus, their role as functional APCs for a primary antiviral immune response in the CNS remains to be confirmed.

It is interesting to note that ≤25% of CD8+ T cells bound class I tetramers at the peak of the proliferative response. This suggests that most brain infiltrating CD8+ T cells are either not specific for VSV. However, it should be noted that while C57BL/6 mice recognise a single immunodominant epitope for VSV (H-2Db restricted), Balb/c mice can recognise two epitopes for VSV (H-2Ld and H-2Dd restricted) (Forman et al., 1983). The CB6F1 mice used in these studies may therefore be able to recognise both VSV epitopes, whereas the tetramers used recognised only the H-2Dd restricted antigen. A novel VSV cryptic determinant displayed in the CNS but not in the periphery may be another possible explanation for the lack of antigen specificity among infiltrating T cells. Recent studies demonstrated an antigen-specific pathway for CD8+ T cells across the BBB (Galea et al., 2007a, 2007b). It is perhaps not surprising that non-specific CD8+ T cells infiltrate the brain. VSV upregulates both early (CD25, CD69) and late (CD11a, CD49d) activation antigens on essentially all CD8+ and CD4+ T cells by a DC-independent mechanism (Fig. 5, data not shown) and expression of some of these activation antigens (CD49d, VLA-4) may be required for penetration of the BBB. VSV also disrupts the BBB and this may also contribute to T cells penetration of the brain parenchyma (Bi et al., 1995b). Thus, both of these factors may contribute to the predominance of CD8+ T cells in the CNS that lack obvious specificity for the inducing virus. It is unclear why activated CD8+ T cells remain in the brain in the absence of cognate antigen. This study suggests that the paradigm that only T cells activated in the DLN infiltrate the CNS may not apply to VSV and other viruses with similar mitogenic properties. For these viruses, non-specific T cell activation and disruption of the BBB may allow CNS penetration of T cells with a variety of specificities. Activated microglia could then function as APCs to induce or propagate a primary antiviral T cell-mediated immune response within the CNS and not the CLN. Additional studies in this model are underway to test this hypothesis.

We previously reported that depletion of conventional and pDCs with DT treatment markedly inhibited clonal expansion of naïve CD8+ VSV-N T cells in non-neuronal sites (Clavarra et al., 2006). However, recent studies by Probst et al. (2005) questioned the specificity of this ablation model because they reported that DCs and mH were depleted by DT treatment of DTRtg mice. In our experience, the dose of DT used by these investigators was toxic and killed a significant percentage of mice prior to virus infection. Furthermore, we titrated the dose of DT administered to deplete DCs and found efficient and systemic
depletion of DCs was achieved with as little as 0.5 ng/g DT (data not shown) without any detectable morbidity. We also observed that different commercial preparations of DT vary in toxicity and potency. The lowest dose (per preparation of DT) that efficiently and specifically depleted DCs in vivo was used in the studies presented in this report.

Our current studies expand the observed inhibition of CD8+ VSV-N T cells resulting from DT treatment to include the CNS. Thus, in both the periphery and the CNS, clonal expansion of naive VSV-specific T cells is in DC-dependent, an observation consistent with studies demonstrating that CNS DCs are crucial for antigen presentation to CD4+ T cells (Bailey et al., 2007; Miller et al., 2007). Ablation of DCs also profoundly inhibited VSV encephalitis. These results were somewhat surprising, given that the traditional role for DCs in the brain is primarily as an activator of naive T cells. The mechanistic basis for the failure of peripheral blood cells to infiltrate the brain in mice depleted of peripheral DCs remains to be clarified. Although DT can penetrate the blood–brain barrier and has been used to selectively kill oligodendrocytes in a similar DTR depletion model (Buch et al., 2005; Gropp et al., 2005), this required a high dose of DT (100 ng/injection) and 3 injections/day for one week. Diphtheria toxin has a very short serum T1/2 life (90% cleared in 6 h) with poor CNS penetrance (low blood/CNS transfer constant) (Wrobel et al., 1990), and this may explain why multiple high dose injections were required to deplete oligodendrocytes. Thus, it is very unlikely that we depleted DCs in the brain because such treatment conditions were not employed in our studies (≤20 ng/injection, two injections). This view is further supported by the observation that microgliosis was not diminished by DT treatment despite upregulation of CD11c during virus infection (data not shown). These studies imply that activated microglia are not sufficient for a normal inflammatory response to VSV indicating that peripheral DCs provide a unique and essential function in the CNS. This function could be early chemokine production by these cells or, alternatively, reflect a DC–glial cell interaction essential for chemokine production and blood cell infiltration into the CNS. Although the lack of T cell infiltration is in keeping with the paradigm of lymphocyte activation in the CLN, the infiltration of monocytic cells was also profoundly inhibited by depletion of DCs. Previous characterization of the DTR model and our titration of DT demonstrated that our dosage did not deplete macrophages (Ciavarra et al., 2006); therefore, peripheral DC apparently play a role above and beyond that of T cell activation in regulation of the CNS immune response.

Although DC ablation profoundly inhibited CNS inflammation and proliferation of VSV-N T cells, it reduced neither microglia nor the secretion of IFN-γ in response to viral infection. While IFN-γ is primarily considered a product of T cells, the levels observed in the brains of mice do not correspond with T cell inactivation in regulation of the CNS immune response dependent on peripheral DCs is currently being investigated.

Materials and methods

Mice

To assess DC function in vivo, we utilized a recently described transgenic mouse model that allows for the selective ablation of DCs in vivo. Diphtheria toxin (DT) receptor transgenic (DTRtg) mice (C57BL/6-Tg(Ifgtax-DTR/EGFP)57Lan/J) were purchased from Jackson Laboratories (Bar Harbor, ME) and subsequently bred to C57BL/6 mice (also purchased from Jackson Laboratories) to generate CB6F1 mice. The transgenic F1 mice are subsequently referred to DTRtg mice for simplicity. DTRtg mice possess a hybrid gene composed of the simian DTR and green fluorescent protein (GFP) under the control of the CD11c promoter. Mice injected with DT show rapid depletion of DCs from the spleen, lymph nodes, nasal mucosa, lungs, bladder, peritoneal fluid, thymus, and blood (Ciavarra et al., 2006; Engel et al., 2006; Jung et al., 2002; Kleinjan et al., 2006). Expression of the simian diphtheria toxin receptor was confirmed by multiplex PCR as previously described (Ciavarra et al., 2006; Genotyping Protocol for Itgax-DTR/GFP, 2007). Primer pairs were purchased from Integrated DNA Technologies, Coraville, IA. Mice lacking the transgene were used as non-DTRtg controls. Although flow cytometry for CD11c+ cells is often used to assess depletions of DCs, we have determined that the most sensitive indicator of DC depletion is the loss of T cell activation and clonal expansion (Ciavarra et al., 2006).
plaque assays (Sekellick and Marcus, 1979). Mice were infected with either $5 \times 10^4$ (male) or $2 \times 10^5$ (female) PFU VSV by i.n. inoculation of 5 μL/nostril (Barna et al., 1996). For depletion of dendritic cells, mice were treated i.p. with 2 ng/g DT (Sigma, St. Louis, MO) one day before and after virus infection. Mice were euthanized at various time points post-infection by CO$_2$ asphyxiation. All mice were utilized at 6–10 weeks of age following protocols approved by the Institutional Animal Care and Use Committee according to federal guidelines.

**Multicolour flow cytometry**

Brains were excised and individually homogenized in a glass Tenbroek homogenizer with 2 mL PBS for 20 strokes. Cell suspensions were centrifuged for 8 min at 300 ×g. Supernatants were stored separately and the cell pellets were subjected to discontinuous Percoll centrifugation. Briefly, cells were resuspended in 70% Percoll overlaid with 35% Percoll and PBS, then centrifuged for 45 min at 20 °C and 1200 ×g. The cells at the 35–70% interface were collected, diluted with mAbs to CD45, CD8, and the activation antigen CD49d. CD8$^+$ cells were gated and the percentage of VSV-specific T cells within this gate determined by tetramer staining and co-expression of CD49d. Brains from 3 to 5 mice were pooled within each group. This experiment has been repeated two additional times and yielded similar results.

Fig. 5. Ablation of peripheral dendritic cells in vivo markedly suppresses the CNS innate and adaptive antiviral immune responses. (A) DTRTg mice were given either PBS or DT one day before and after intranasal instillation of VSV (2 × 10$^5$ PFU). Mice were then monitored for morbidity (panel a). Mice were euthanized when moribund and brains and peripheral organs evaluated for VSV titres by plaque assay (panel b). This data is derived from 17 VSV-infected mice and 18 DT-treated, VSV-infected mice. (B) Mice were treated with either PBS (panels a, c) or DT (panels b, d). Cohorts either remained uninfected (panels a, b) or were given an intranasal inoculation of VSV at $2 \times 10^5$ PFU/mouse (panels c, d). Six days post-infection, brains were homogenized and then subjected to Percoll gradient centrifugation to enrich for leukocytes. Cells were then phenotyped by flow cytometry and a microglia gate defined as CD11b$^+$CD45$^{low/int}$ cells (panel a, R1 gate). A second gate was established for peripheral mφ/monocytes defined as CD11b$^+$CD45$^{high}$ (panel c, R2). A final CD11b$^-$CD45$^{high}$ gate was used to evaluate lymphocytes (panel d, R3). (C) The percent positive and absolute number of cells was then calculated within each of these gates and is summarized in the bar graphs. (D) To identify CD8$^+$ VSV-specific T cells, cells were first incubated with H-2Kb/VSV-N52$^{5-59}$ tetramers and then stained with mAbs to CD45, CD8, and the activation antigen CD49d. Brains from 3 to 5 mice were pooled within each group. This experiment has been repeated two additional times and yielded similar results.
CD45-low/int) or in forward and side scatter characteristics. The percentage of microglia experiment is representative of two additional experiments. Averaged and expressed as the mean±SEM (top panel). The total number of IFN-γ, clone BVD6-24G2; IFN-γ, clone JES6-5H4; IL-4, clone 11B11; IFN-γ, clone R4-6A2; all purchased from eBioscience. No exogenous virus was added during infection of the central nervous system. The work was supported by a grant from the National Institutes of Health Grant (NIAID48700) awarded to R.P. C.

Fig. 6. Systemic ablation of peripheral dendritic cells does not suppress the virus-induced IFN-γ response in the CNS. Mice were given a single intranasal instillation of VSV after being treated with either PBS (VSV) or DT (DT+VSV). Control mice were not infected (mock). Six days post-infection, brains were removed, pooled and leukocytes isolated by Percoll gradient centrifugation. Cells were seeded into ELISPOT plates in triplicate at up to 2 x 10^5 cells/well and incubated overnight. No exogenous virus or viral peptide was added to these cultures. The following day plates were developed and the number of ELISPOTs/input cell number determined under a dissecting microscope.

The number of ELISPOTs/10^6 cells determined for each triplicate input cell number was then calculated based on this value and cell recoveries (bottom panel) per organ. Brains from 4 to 5 mice were pooled within each group. This experiment is representative of two additional experiments.

References


Bi, Z., Quandt, P., Komatsu, T., Barna, M., Reiss, C.S., 1995b. IL-12 promotes enhanced recovery from vascular stomatitis virus infection of the central nervous system. J. Immunol. 155 (12), 5848–5859.


Dimier-Poisson, I., Aline, F., Bout, D., Mevelec, M.N., 2006. Induction of protective immunity against toxoplasmosis in mice by immunization with Toxoplasma gondii RNA. Vaccine 24 (10), 1705–1709.


